RxDoctor Payments Data

Melissa Aswad, PA

Physician Assistant · Glendale, AZNPI 1760077275

Payments from drug & device makers

$1,572in general payments, 2019–2025

Across 24 payments — averaging $65.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$333
  • Johnson & Johnson$240
  • Gilead$131
  • Intuitive Surgical$126
  • AstraZeneca$122
  • EMD Serono, Inc.$121
  • plus $499 from 8 others

What the payments were for

  • Food & beverage$1,38788%
  • Education$18512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,572 in reported general payments places this provider in the 75th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$39,624
Medicare patients
258
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide63$803,667
BrukinsaZanubrutinib44$603,013
Lenalidomide36$489,832
ImbruvicaIbrutinib29$477,041
RevlimidLenalidomide23$474,699
TasignaNilotinib Hcl18$386,795
JakafiRuxolitinib Phosphate22$350,293
ErleadaApalutamide15$258,734
EliquisApixaban137$155,827
PromactaEltrombopag Olamine11$97,109
XareltoRivaroxaban66$71,783
Abiraterone Acetate21$5,613
Letrozole89$2,251
Exemestane14$1,755
Hydroxyurea54$1,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna, Promacta$42$483,90429 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$118$477,04129 claims
Bristol Myers SquibbRevlimid$49$474,69923 claims
Johnson & JohnsonErleada, Xarelto$240$330,51781 claims
PfizerEliquis$112$155,827137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →